Antenatal magnesium sulphate exposure is associated with prolonged parathyroid hormone suppression in preterm neonates

The effects of maternal magnesium sulphate treatment on neonatal mineral status and parathyroid hormone secretory response were studied in 8 exposed and 27 control preterm infants during the first 2 wk of life. Antenatal magnesium sulphate resulted in hypermagnesaemia during the first 3-7 d of life...

Full description

Saved in:
Bibliographic Details
Published in:Acta pædiatrica (Oslo) 2001-03, Vol.90 (3), p.278-281
Main Authors: RANTONEN, T, KÄÄPÄ, P, JALONEN, J, EKBLAD, U, PELTOLA, O, VÄLIMÄKI, I, KERO, P
Format: Article
Language:English
Subjects:
Biological and medical sciences
Calcium - blood
Calcium - urine
Drug toxicity and drugs side effects treatment
Female
Fetal Blood - chemistry
Humans
Infant, Newborn
Infant, Premature
Magnesium - blood
Magnesium - urine
Magnesium Sulfate - adverse effects
Magnesium Sulfate - therapeutic use
Medical sciences
Miscellaneous (drug allergy, mutagens, teratogens...)
Parathyroid Hormone - blood
Parathyroid Hormone - deficiency
Pharmacology. Drug treatments
Phosphorus - blood
Phosphorus - urine
Pre-Eclampsia - drug therapy
Pregnancy
Tocolytic Agents - adverse effects
Tocolytic Agents - therapeutic use
Trace Elements - blood
Trace Elements - urine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effects of maternal magnesium sulphate treatment on neonatal mineral status and parathyroid hormone secretory response were studied in 8 exposed and 27 control preterm infants during the first 2 wk of life. Antenatal magnesium sulphate resulted in hypermagnesaemia during the first 3-7 d of life without affecting other serum mineral concentrations. Early hypermagnesaemia was associated with hypercalciuria during the first 3 d and parathyroid hormone suppression up to the age of 2 wk in the exposed infants.
ISSN:0803-5253
1651-2227
DOI:10.1080/08035250121590